Alexion Pharmaceuticals Tops Expectations in Q2

Alexion Pharmaceuticals (NASDAQ: ALXN) gave investors a lot to like when it announced its first-quarter results in April. Revenue increased by 23% year over year, while adjusted earnings were up by 42%.

The biotech announced its second-quarter results before the market opened on Wednesday. And Alexion again provided plenty of reasons for investors to be happy. Here are the highlights from the company's Q2 update.

Image source: Getty Images.

Continue reading

Quelle Fool.com